	Pembrolizumab		Nivolumab		all immunotherapy drugs		chemotherapy	
	N	%	N	%	N	%	N	%
All	373	100	1393	100	1810	100	24224	100
sex								
p-value of difference with chemotherapy	P=0.9570		P=0.0512		P=0.0654		Control Group	
F	164	43.97	571	40.99	750	41.44	10584	43.69
M	209	56.03	822	59.01	1060	58.56	13640	56.31
ethnicity								
p-value of difference with chemotherapy	P=0.3657		P<0.0001		P<0.0001		Control Group	
African American/Black	1	0.27	17	1.22	19	1.05	170	0.7
American Indian/Alaskan Native	0	0	1	0.07	1	0.06	13	0.05
Asian	3	0.8	4	0.29	7	0.39	84	0.35
Black (Non-Hispanic)	0	0	0	0	0	0	4	0.02
Caucasian (Non-Hispanic)	1	0.27	1	0.07	2	0.11	24	0.1
Hispanic/Latino	1	0.27	10	0.72	11	0.61	68	0.28
Other	1	0.27	6	0.43	7	0.39	39	0.16
Pacific Islander	0	0	0	0	0	0	7	0.03
Two or more races	5	1.34	14	1.01	20	1.1	192	0.79
White	49	13.14	201	14.43	258	14.25	2386	9.85
Unknown	312	83.65	1139	81.77	1485	82.04	21237	87.67
age								
p-value of difference with chemotherapy	P=0.0018		P=0.0558		P=0.1071		Control Group	
[0,40)	13	3.49	15	1.08	28	1.55	335	1.38
[40,50)	22	5.9	60	4.31	86	4.75	1363	5.63
[50,60)	75	20.11	288	20.67	378	20.88	5548	22.9
[60,70)	116	31.1	507	36.4	635	35.08	8433	34.81
[70,80)	96	25.74	376	26.99	481	26.57	6121	25.27
[80,120)	51	13.67	147	10.55	202	11.16	2424	10.01
post-matching size	297	79.62	1107	79.47	1431	79.06	Control Group	